Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.

AIMS: To explore the effect of liraglutide treatment on serum adropin and its relationship to the liver fat content in newly diagnosed patients with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated fatty liver disease (MAFLD). METHODS: Serum adropin level and liver fat content were assessed in patients with T2DM and MAFLD (n = 22), along with healthy controls (n = 22). Afterward, the patients received liraglutide treatment for 12 weeks. Serum adropin levels were examined by a competitive enzyme-linked immunosorbent assay. Liver fat content was quantified via magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF). RESULTS: We found that patients with newly diagnosed T2DM and MAFLD had lower serum adropin levels [2.79 ± 0.47 vs. 3.27 ± 0.79 ng/mL, P < 0.05] and higher liver fat content [19.12 ± 9.46 vs. 4.67 ± 0.61%, P < 0.001], compared to healthy controls. Following 12-week liraglutide treatment, serum adropin levels increased from 2.83(2.44, 3.24) to 3.65(3.20, 3.85) ng/mL (P < 0.001), and liver fat content decreased from 18.04(11.08, 27.65) to 7.74(6.42, 13.49) % (P < 0.001) in patients with T2DM and MAFLD. Furthermore, increases in serum adropin were strongly associated with decreases in liver fat content (β = - 5.933, P < 0.001), liver enzyme and glucolipid metabolism parameters. CONCLUSION: The increase in serum adropin level following liraglutide treatment was strongly correlated with the reduction in liver fat content and glucolipid metabolism. Hence, adropin might be a potential marker for the beneficial effects of liraglutide on treating T2DM and MAFLD.